If symptoms persist beyond 5 to 7 days or worsen, contact your healthcare provider for evaluation
Immediate medical attention (emergency department or urgent care) is warranted for: Signs of anaphylaxis or severe allergic reaction, including difficulty breathing, throat tightness, rapid pulse, dizziness, or widespread urticaria (call 911) Severe swelling extending beyond the injection site or involving the face, lips, or tongue Signs of significant infection, including fever above 100.4F (38C), purulent drainage, or rapidly spreading erythema with warmth Severe pain disproportionate to visible findings Skin necrosis, blistering, or ulceration at the injection site Scheduled healthcare provider evaluation is appropriate for: Persistent injection site reactions lasting more than 5 to 7 days despite conservative management Recurrent moderate to severe reactions with each injection, suggesting possible hypersensitivity Development of indurated nodules or lipohypertrophy at injection sites Uncertainty about whether symptoms represent normal reactions or require intervention Clinical assessment of concerning injection site reactions typically includes examination of the affected area, review of injection technique, and evaluation for signs of infection or hypersensitivity
GLP-1 receptor agonists are not currently recommended during breastfeeding due to insufficient safety data in lactating individuals, though some providers weigh individual circumstances against documented risks
LIPO-C+ supplied by Neogenesis Bio Labs is intended exclusively for in-vitro research, laboratory study, and scientific investigation
Understanding your genetic and biomarker profile can support a more informed conversation with your prescriber about whether Lipo C + tirzepatide aligns with your metabolic needs, expected efficacy timeline, and monitoring plan
